SRX OS vs PFS, page-8

Legume, thanks for sharing the link to the article. Will be interesting to see if liver-PFS result translates to an OS benefit, in the meantime we wait to see to what extent the present findings influence practice.

Disagree with you on point 4, I don't see any rationale as to why a prolonged liver PFS would have a negative impact at other sites. Liver PFS was 2 months longer than overall PFS in the control arm, maybe progression at extrahepatic sites such as lung either occurs earlier or is easier to detect earlier. My interpretation is that some liver only patients must have progressed outside the liver. Maybe they had micromets that couldn't be detected. If there were a detrimental impact of SIRT on other sites (can't see how) then the overall PFS median would be reduced